K. Scorsune

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, The Lancet. Haematology.

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

G. Alter, S. Fischinger, J. Abramson, 2022, Blood Advances.